Article
TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2026
Di Federico Alessandro, Hong Lingzhi, Elkrief Arielle, Thummalapalli Rohit, Cooper Alissa J, Ricciuti Biagio, Digumarthy Subba, Alessi Joao V, Gogia Pooja, Hambelton Grace M, Pecci Federica, Makarem Maisam, Gandhi Malini M, Garbo Edoardo, De Giglio Andrea, Gagliano Ambrogio, Sperandi Francesca, Gelsomino Francesco, Scalera Stefano, Cipriani Laura, Marinelli Daniele, Lamberti Giuseppe, Shaverdian Narek, Haradon Jessica, Nguyen Tom, Voligny Emma, Ladanyi Marc, Zhang Jianjun, Gibbons Don L, Heymach John V, Nishino Mizuki, Rodig Scott J, Pfaff Kathleen, Wang Xinan, Rekhtman Natasha, Sholl Lynette M, Luo Jia, Johnson Bruce E, Janne Pasi A, Arvind Ravi, Gainor Justin F, Maugeri-Saccà Marcello, Ardizzoni Andrea, Heist Rebecca S, Arbour Kathryn C, Schoenfeld Adam J, Vokes Natalie I, Awad Mark M
Abstract excerpt
INTRODUCTION: Thyroid transcription factor-1 (TTF-1) expression, routinely assessed through immunohistochemistry in the diagnostic evaluation of lung adenocarcinomas (LUADs), is negative (TTF-1Neg) in approximately 15% to 20% of cases. Although worse outcomes have been reported for these tumors compared with TTF-1-positive (TTF-1Pos) LUAD, a comprehensive characterization of TTF-1 negativity is currently lacking....
Topics
Join the communities discussing this publication.